1. Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer.
- Author
-
Rui Xiong, Jiong Zhao, Gutgesell, Lauren M., Yueting Wang, Sue Lee, Karumudi, Bhargava, Huiping Zhao, Yunlong Lu, Tonetti, Debra A., and Thatcher, Gregory R. J.
- Subjects
- *
SELECTIVE estrogen receptor modulators , *BREAST cancer treatment , *DRUG development , *AROMATASE inhibitors , *DRUG resistance in cancer cells - Abstract
Resistance to the selective estrogen receptor modulator tamoxifen and to aromatase inhibitors that lower circulating estradiol occurs in up to 50% of patients, generally leading to an endocrine-independent ER+ phenotype. Selective ER downregulators (SERDs) are able to ablate ER and thus, theoretically, to prevent survival of both endocrine-dependent and -independent ER+ tumors. The clinical SERD fulvestrant is hampered by intramuscular administration and undesirable pharmacokinetics. Novel SERDs were designed using the 6-OH-benzothiophene (BT) scaffold common to arzoxifene and raloxifene. Treatment-resistant (TR) ER+ cell lines (MCF-7:5C and MCF-7:TAM1) were used for optimization, followed by validation in the parent endocrine-dependent cell line (MCF-7:WS8), in 2D and 3D cultures, using ERα in-cell westerns, ERE-luciferase, and cell viability assays, with 2 (GDC-0810/ARN-810) used for comparison. Two BT SERDs with superior in vitro activity to 2 were studied for bioavailability and shown to cause regression of a TR, endocrine-independent ER+ xenograft superior to that with 2. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF